At today's FDA advisory committee meeting, Amgen will present Repatha clinical trial data from approximately 6,800 patients, including more than 4,500 patients with high cholesterol in 10 Phase 3 ...

Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...

HOUSAND OAKS, Calif., Amgen today announced that a new analysis of the cardiovascular outcomes study (FOURIER) demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) levels with ...

About Repatha (evolocumab) Repatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and inhibits circulating PCSK9 from ...

If approved by the European Commission (EC), Repatha would be the first PCSK9 inhibitor in Europe with the option of a single monthly injection. Repatha was the first PCSK9 inhibitor to gain marketing ...

--Amgen today announced new Repatha ® combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN- DOSE study of investigational olpasiran, an siRNA that ...

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current ...

THOUSAND OAKS, Calif., Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high cholesterol ...

THOUSAND OAKS, Calif., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to include a new indication ...

BRUSSELS, BELGIUM — Evolocumab (Repatha, Amgen), one of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, is the first of these agents approved in Europe for the treatment of patients ...